Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks

Dirk Rades, Primoz Strojan, Daniel Seidl, Stefan Janssen, Amira Bajrovic, Nadja Kazic, Samer G. Hakim, Barbara Wollenberg, Steven E. Schild

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m2 cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m2 cisplatin plus 600/1000 mg/m2 5-FU on days 1–5 and days 29–33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m2 of cisplatin require close monitoring of their renal function.

Original languageEnglish (US)
Pages (from-to)1436-1440
Number of pages5
JournalJournal of Cranio-Maxillo-Facial Surgery
Volume44
Issue number9
DOIs
StatePublished - 2016

Fingerprint

Chemoradiotherapy
Fluorouracil
Cisplatin
Survival
Hemoglobins
Multivariate Analysis
Drug Therapy
Renal Insufficiency
Carcinoma, squamous cell of head and neck
Kidney

Keywords

  • Adverse events
  • Cisplatin
  • Cisplatin/5-FU
  • LASCCHN
  • Outcomes
  • Radiochemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology

Cite this

Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck : Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. / Rades, Dirk; Strojan, Primoz; Seidl, Daniel; Janssen, Stefan; Bajrovic, Amira; Kazic, Nadja; Hakim, Samer G.; Wollenberg, Barbara; Schild, Steven E.

In: Journal of Cranio-Maxillo-Facial Surgery, Vol. 44, No. 9, 2016, p. 1436-1440.

Research output: Contribution to journalArticle

Rades, Dirk ; Strojan, Primoz ; Seidl, Daniel ; Janssen, Stefan ; Bajrovic, Amira ; Kazic, Nadja ; Hakim, Samer G. ; Wollenberg, Barbara ; Schild, Steven E. / Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck : Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. In: Journal of Cranio-Maxillo-Facial Surgery. 2016 ; Vol. 44, No. 9. pp. 1436-1440.
@article{8076370dcb904a59938e00ea6794db5a,
title = "Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks",
abstract = "Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m2 cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m2 cisplatin plus 600/1000 mg/m2 5-FU on days 1–5 and days 29–33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m2 of cisplatin require close monitoring of their renal function.",
keywords = "Adverse events, Cisplatin, Cisplatin/5-FU, LASCCHN, Outcomes, Radiochemotherapy",
author = "Dirk Rades and Primoz Strojan and Daniel Seidl and Stefan Janssen and Amira Bajrovic and Nadja Kazic and Hakim, {Samer G.} and Barbara Wollenberg and Schild, {Steven E.}",
year = "2016",
doi = "10.1016/j.jcms.2016.06.033",
language = "English (US)",
volume = "44",
pages = "1436--1440",
journal = "Journal of Cranio-Maxillo-Facial Surgery",
issn = "1010-5182",
publisher = "Churchill Livingstone",
number = "9",

}

TY - JOUR

T1 - Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck

T2 - Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks

AU - Rades, Dirk

AU - Strojan, Primoz

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Kazic, Nadja

AU - Hakim, Samer G.

AU - Wollenberg, Barbara

AU - Schild, Steven E.

PY - 2016

Y1 - 2016

N2 - Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m2 cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m2 cisplatin plus 600/1000 mg/m2 5-FU on days 1–5 and days 29–33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m2 of cisplatin require close monitoring of their renal function.

AB - Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m2 cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m2 cisplatin plus 600/1000 mg/m2 5-FU on days 1–5 and days 29–33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m2 of cisplatin require close monitoring of their renal function.

KW - Adverse events

KW - Cisplatin

KW - Cisplatin/5-FU

KW - LASCCHN

KW - Outcomes

KW - Radiochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84999176921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999176921&partnerID=8YFLogxK

U2 - 10.1016/j.jcms.2016.06.033

DO - 10.1016/j.jcms.2016.06.033

M3 - Article

C2 - 27499514

AN - SCOPUS:84999176921

VL - 44

SP - 1436

EP - 1440

JO - Journal of Cranio-Maxillo-Facial Surgery

JF - Journal of Cranio-Maxillo-Facial Surgery

SN - 1010-5182

IS - 9

ER -